Disease caused by the bacterium Streptococcus pneumoniae (pneumococcus) is the most common cause of preventable death in children and a major cause of death among adults world-wide.
The current conjugate vaccine is effective in
Disease caused by the bacterium Streptococcus pneumoniae (pneumococcus) is the most common cause of preventable death in children and a major cause of death among adults world-wide.
The current conjugate vaccine is effective in the prevention of both pneumococcal carriage and disease in young children however, it is not as effective against pneumonia and otitis media (ear infection) and it only prevents infection by a small number of pneumococcal types. As such, there is a need for new vaccines and it has recently been suggested that pneumococcal carriage, rather than disease, could be used as an endpoint in vaccine trials.
LSTM’s Vaccine, Immunology and Translational Research Team (VITal), part of the Department of Clinical Sciences at LSTM and the Respiratory Research at the Royal at the RLUH, has developed an experimental human pneumococcal carriage model over the last six years that can be used to test pneumococcal vaccines in development. Demonstrating a reduction in experimental carriage acquisition would provide proof-of-concept for both individual protection and potential reduction in bacterial transmission. The team recently completed a double blind randomized controlled trial using the current conjugate vaccine, PCV13, and demonstrated that acquisition of experimental pneumococcal carriage was reduced by 78% in vaccinated adults, which is similar to what has be